Ask about mood when you start and review a psoriasis biologic

Design

Systematic review and network meta-analysis of RCTs and prospective cohorts

Population

4,319 adults with moderate-to-severe plaque psoriasis in 8 studies

Primary outcome

Change in depression and anxiety symptoms

Effect

Depression SMD 0.68 (95% CI 0.47-0.88) for IL-12/23; anxiety SMD 0.46 for IL-23 and IL-12/23

Depression and anxiety are common in moderate-to-severe psoriasis. This systematic review and network meta-analysis pooled randomised trials and prospective cohorts, eight studies and 4,319 adults, to compare how biologics affect those symptoms.

Every biologic class was associated with short-term improvement in depressive and anxiety symptoms against placebo. IL-12/23 inhibitors had the largest estimate for depression (SMD 0.68, 95% CI 0.47-0.88); for anxiety, IL-23 and IL-12/23 inhibitors had the same estimate (SMD 0.46). At the level of individual drugs, rankings were uncertain because the network was sparse and certainty ranged from high to low.

Mood improvement generally accompanied skin improvement but was not strictly proportional to it, so clearing the skin does not guarantee better mood and vice versa.

The practical change is to treat mood as an outcome. Use a brief screening question or validated tool at baseline and at review, and refer when symptoms persist despite skin response. Do not choose between biologics on these mood estimates.

• Screen for depression and anxiety before starting a biologic for psoriasis.
• Repeat the screen at review; mood change can lag or diverge from skin response.
• All biologic classes were associated with short-term mood improvement over placebo.
• Do not pick one biologic over another on mood data — rankings were uncertain.
• Refer to mental health services when symptoms persist despite good skin control.

Why it matters

Mood is part of the benefit a biologic delivers, and clearing the skin alone does not show you whether it has improved.

Don't overread it

Drug-level rankings were uncertain, so this does not show one biologic is better for mood than another.

The statistics, in plain English

A standardised mean difference of about 0.5-0.7 is a moderate effect. The intervals exclude zero, so the improvement over placebo is unlikely to be chance. But with a sparse network, the ordering of individual drugs could easily change with new trials.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.